This is a repository copy of *Body mass index and survival in women with breast cancer--systematic literature review and meta-analysis of 82 follow-up studies*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/78837/

Version: WRRO with coversheet

**Article:**
Chan, DS, Vieira, AR, Aune, D et al. (7 more authors) (2014) Body mass index and survival in women with breast cancer--systematic literature review and meta-analysis of 82 follow-up studies. Annals of Oncology. ISSN 0923-7534

https://doi.org/10.1093/annonc/mdu042

---

**Reuse**
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher’s website.

**Takedown**
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
This is an author produced version of a paper published in **Annals of Oncology**.

White Rose Research Online URL for this paper:

[http://eprints.whiterose.ac.uk/78837/](http://eprints.whiterose.ac.uk/78837/)

**Paper:**

[http://dx.doi.org/10.1093/annonc/mdu042](http://dx.doi.org/10.1093/annonc/mdu042)
Article type: Review

**Body mass index and survival in women with breast cancer – systematic literature review and meta-analysis of 82 follow-up studies**

D. S. M. Chan¹, A. R. Vieira¹, D. Aune¹,², E. V. Bandera³, D. C. Greenwood⁴, A. McTiernan⁵, D. Navarro Rosenblatt¹, I. Thune⁶,⁷, R. Vieira⁸, T. Norat¹

**Affiliations:**

¹ Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom

² Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway

³ Rutgers Cancer Institute of New Jersey, The State University of New Jersey, New Jersey, United States

⁴ Division of Biostatistics, University of Leeds, Leeds, United Kingdom

⁵ Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Washington, United States

⁶ Department of Oncology, Oslo University Hospital, Oslo, Norway

⁷ Faculty of Health Sciences, Department of Community Medicine, University of Tromso, Tromso, Norway

⁸ School of Mathematics and Statistics, University of Newcastle, Newcastle upon Tyne, United Kingdom

**Short title:** Body mass index and survival in women with breast cancer

**Corresponding author:** Ms Doris S. M. Chan

Address: Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, St Mary’s Campus, Norfolk Place, London, W2 1PG, United Kingdom
Email: d.chan@imperial.ac.uk

Tel no.: +44 (0)20 759 48590

Fax no.: +44 (0)20 759 43193

**Abbreviations:** AICR - American Institute for Cancer Research; BMI – body mass index; CI – confidence interval; QI – Quetelet’s Index; RR – relative risk; WCRF – World Cancer Research Fund; WHO – World Health Organisation
abstract

Background: Positive association between obesity and survival after breast cancer was demonstrated in previous meta-analyses of published data, but only the results for the comparison of obese versus non-obese was summarised.

Methods: We systematically searched in Medline and Embase for follow-up studies of breast cancer survivors with body mass index (BMI) before and after diagnosis and total and cause-specific mortality until June 2013, as part of the World Cancer Research Fund Continuous Update Project. Random-effects meta-analyses were conducted to explore the magnitude and the shape of the associations.

Results: Eighty-two studies, including 213,075 breast cancer survivors with 41,477 deaths (23,182 from breast cancer) were identified. For BMI before diagnosis, compared with normal weight women, the summary relative risks (RR) of total mortality were 1.41 [95% confidence interval (CI) 1.29-1.53] for obese (BMI \( \geq 30.0 \)), 1.07 (95 CI 1.02-1.12) for overweight (BMI 25.0-<30.0) and 1.10 (95% CI 0.92-1.31) for underweight (BMI <18.5) women. For obese women, the summary RRs were 1.75 (95% CI 1.26-2.41) for premenopausal and 1.34 (95% CI 1.18-1.53) for postmenopausal breast cancer. For each 5 kg/m\(^2\) increment of BMI before, <12 months after, and ≥12 months after diagnosis, increased risks of 17%, 11%, and 8% for total mortality and 18%, 14%, and 29% for breast cancer mortality were observed, respectively.

Conclusions: Overweight and obesity are associated with poorer overall and breast cancer survival in pre and postmenopausal breast cancer. Randomised clinical trials are needed to test interventions for weight loss and maintenance on survival in women with breast cancer.

Keywords: Body mass index, survival after breast cancer, systematic literature review, meta-analysis
**introduction**

The number of female breast cancer survivors is growing because of longer survival as a consequence of advances in treatment and early diagnosis. There were approximately 2.6 million female breast cancer survivors in US in 2008[1], and in the UK, breast cancer accounted for approximately 28% of the 2 million cancer survivors in 2008[2].

Obesity is a pandemic health concern, with over 500 million adults worldwide estimated to be obese and 958 million were overweight in 2008[3]. One of the established risk factors for breast cancer development in postmenopausal women is obesity[4], which has further been linked to breast cancer recurrence[5] and poorer survival in pre and postmenopausal breast cancer[6,7]. Preliminary findings from randomised controlled trials suggest that lifestyle modifications improved biomarkers associated with breast cancer progression and overall survival[8].

The biological mechanisms underlying the association between obesity and breast cancer survival are not established, and could involve interacting mediators of hormones, adipocytokines, and inflammatory cytokines which link to cell survival or apoptosis, migration, and proliferation[9]. Higher level of estradiol produced in postmenopausal women through aromatisation of androgens in the adipose tissues[10], and higher level of insulin[11], a condition common in obese women, are linked to poorer prognosis in breast cancer. A possible interaction between leptin and insulin[12], and obesity-related markers of inflammation[13] have also been linked to breast cancer outcomes. Non-biological mechanisms could include chemotherapy under-dosing in obese women, suboptimal treatment, and obesity-related complications[14].

Numerous studies have examined the relationship between obesity and breast cancer outcomes and past reviews have concluded that obesity is linked to a lower survival; however, when investigated in a meta-analysis of published data, only the results of obese
compared with non-obese or lighter women were summarised[6,7,15].

We performed a systematic literature review and meta-analysis of published studies to explore the magnitude and the shape of the association between body fatness, as measured by body mass index (BMI), and the risk of total and cause-specific mortality, overall and in women with pre and postmenopausal breast cancer. As body weight may change close to diagnosis and during primary treatment of breast cancer[16], we examined BMI in three periods: before diagnosis, less than 12 months after diagnosis, and 12 months or more after breast cancer diagnosis.

**materials and methods**

**data sources and search**

We performed a systematic literature search, limited to publications in English, for articles on BMI and survival in women with breast cancer in OVID Medline and Embase from inception to 30 June 2013 using the search strategy implemented for the WCRF/AICR Continuous Update Project on breast cancer survival. The search strategy contained medical subject headings and text words that covered a broad range of factors on diet, physical activity, and anthropometry. The protocol for the review is available at http://www.dietandcancerreport.org/index.php[17]. In addition, we hand-searched the reference lists of relevant articles, reviews, and meta-analysis papers.

**study selection**

Included were follow-up studies of breast cancer survivors, which reported estimates of the associations of BMI ascertained before and after breast cancer diagnosis with total or cause-specific mortality risks. Studies that investigated BMI after diagnosis were divided into two groups: BMI less than 12 months after diagnosis (BMI <12 months), and BMI 12 months or more after diagnosis (BMI ≥12 months). Outcomes included total mortality, breast cancer
mortality, death from cardiovascular disease, and death from causes other than breast cancer. When multiple publications on the same study population were found, results based on longer follow-up and more outcomes were selected for the meta-analysis.

**data extraction**

DSMC, TN, and DA conducted the search. DSMC, ARV, and DNR extracted the study characteristics, tumour-related information, cancer treatment, timing and method of weight and height assessment, BMI levels, number of outcomes and population at-risk, outcome type, estimates of association and their measure of variance [95% confidence interval (CI) or P-value], and adjustment factors in the analysis.

**statistical analysis**

Categorical and dose-response meta-analyses were conducted using random-effects models to account for between-study heterogeneity[18]. Summary relative risks (RR) were estimated using the average of the natural logarithm of the relative risks of each study weighted by the inverse of the variance and then un-weighted by applying a random effects variance component which is derived from the extent of variability of the effect sizes of the studies. The maximally adjusted relative risk estimates were used for the meta-analysis except for the follow-up of randomised controlled trials[19,20] where unadjusted results were also included, as these studies mostly involved a more homogeneous study population. BMI or Quetelet’s Index (QI) measured in units of kg/m² was used.

We conducted categorical meta-analyses by pooling the categorical results reported in the studies. The studies used different BMI categories. In some studies, underweight (BMI <18.5 kg/m² according to WHO international classification) and normal weight women (BMI 18.5 to <25.0 kg/m²) were classified together, but in some studies they were classified separately. Similarly, most studies classified overweight (BMI 25.0 to <30.0 kg/m²) and obese (BMI ≥30.0 kg/m²) women separately, but in some studies overweight and obese women were
combined. The reference category was normal weight or underweight together with normal weight, depending on the studies. For convenience, the BMI categories are referred to as underweight, normal weight, overweight and obese in the present review. We derived the relative risks for overweight and obese women compared with normal weight women in two studies[19,21] that had more than four BMI categories using the method of Hamling[22]. Studies that reported results for obese compared with non-obese women were analysed separately.

The non-linear dose-response relationship between BMI and mortality was examined using the best-fitting second order fractional polynomial regression model[23], defined as the one with the lowest deviance. Non-linearity was tested using the likelihood ratio test[24]. In the non-linear meta-analysis, the reference category was the lowest BMI category in each study and relative risks were recalculated using the method of Hamling[22] when the reference category was not the lowest BMI category in the study.

We also conducted linear dose-response meta-analyses, excluding the category underweight when reported separately in the studies, by pooling estimates of relative risk per unit increase (with its standard error) provided by the studies, or derived by us from categorical data using generalised least-squares for trend estimation[25]. To estimate the trend, the numbers of outcomes and population at-risk for at least three BMI categories, or the information required to derive them using standard methods[26], and means or medians of the BMI categories, or if not reported in the studies, the estimated midpoints of the categories had to be available.

When the extreme BMI categories were open-ended, we used the width of the adjacent close-ended category to estimate the midpoints. Where the relative risks were presented by subgroups (age group[27], menopausal status[28,29], stage[30] or subtype[31] of breast cancer, or others[32-34]), an overall estimate for the study was obtained by a fixed-effect model before pooling in the meta-analysis. We estimated the risk increase of death for an
increment of 5 kg/m² of BMI.

To assess heterogeneity, we computed the Cochran Q test and $I^2$ statistic[35]. The cut-points of 30% and 50% were used for low, moderate, and substantial level of heterogeneity. Sources of heterogeneity were explored by meta-regression and subgroup analyses using pre-defined factors, including indicators of study quality (menopausal status, hormone receptor status, number of outcomes, length of follow-up, study design, geographic location, BMI assessment, adjustment for confounders, and others). Small study or publication bias was examined by Egger’s test[36] and visual inspection of the funnel plots. The influence of each individual study on the summary RR was examined by excluding the study in turn[37]. P<0.05 was considered statistically significant. All analyses were conducted using Stata version 12.1 (StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP).

results

A total of 124 publications investigating the relationship of body fatness and mortality in women with breast cancer were identified. We excluded 31 publications, including four publications on other obesity indices[38-41], 12 publications without a measure of association[42-53], and 15 publications superseded by publications of the same study with more outcomes[54-68]. A further 14 publications were excluded because of insufficient data for the meta-analysis (five publications[69-73]) or unadjusted results (nine publications[74-82]), from which nine publications reported statistically significant increased risk of total, breast cancer, or non-breast cancer mortality in obese women (before or <12 months after diagnosis) compared with the reference BMI[69,71-74,76,77,79,82], two publications reported non-significant inverse associations[75,80] and three publications reported no association[70,78,81] of BMI with survival after breast cancer. Hence, 79 publications from
82 follow-up studies with 41,477 deaths (23,182 from breast cancer) in 213,075 breast cancer survivors were included in the meta-analyses (Figure 1). Supplementary Table S1 shows the characteristics of the studies included in the meta-analyses and details of the excluded studies are in supplementary Table S2 (available at Annals of Oncology online). Results of the meta-analyses are summarised in Table 1.

Studies were follow-up of women with breast cancer identified in prospective aetiologic cohort studies (women were free of cancer at enrolment), or cohorts of breast cancer survivors whose participants were identified in hospitals or through cancer registries, or follow-up of breast cancer patients enrolled in case-control studies or randomised clinical trials.

Some studies included only premenopausal women[83-85] or postmenopausal women[21,27,86-94], but most studies included both. Menopausal status was usually determined at time of diagnosis. Year of diagnosis was from 1957-1965[70] to 2002-2009[74]. Patient tumour characteristics and stage of disease at diagnosis varied across studies, and some studies included carcinoma in situ. No all studies provided clinical information on the tumour, treatment, and comorbidities.

Most of the studies were based in North America or Europe. There were three studies from each of Australia[79,95,96], Korea[97,98] and China[99-101]; two studies from Japan[71,102]; one study from Tunisia[103]; and four international studies[19,104-106]. Study size ranged from 96 patients[107] to 24698 patients[97]. Total number of deaths ranged from 56 deaths[93] to 7397 deaths[108] and the proportion of deaths from breast cancer ranged from 22%[27] to 98%[84] when reported. All but eight studies [30,93,94,98,99,109-111] had an average follow-up of more than five years.

**BMI and total mortality**

**categorical meta-analysis.** For BMI before diagnosis, compared with normal weight women,
the summary RRs were 1.41 (95% CI 1.29-1.53, 21 studies) for obese women, 1.07 (95% CI 1.02-1.12, 19 studies) for overweight women, and 1.10 (95% CI 0.92-1.31, 10 studies) for underweight women (Figure 2). For BMI <12 months after diagnosis and the same comparisons, the summary RRs were 1.23 (95% CI 1.12-1.33, 24 studies) for obese women, 1.07 (95% CI 1.02-1.12, 22 studies) for overweight women, and 1.25 (95% CI 0.99-1.57, 11 studies) for underweight women (supplementary Figure S1, available at Annals of Oncology online). Substantial heterogeneities were observed between studies of obese women and underweight women ($I^2 = 69\%, P < 0.01; I^2 = 63\%, P < 0.01$ respectively). For BMI ≥12 months after diagnosis, the summary RRs were 1.21 (95% CI 1.06-1.38, 5 studies) for obese women, 0.98 (95% CI 0.86-1.11, 4 studies) for overweight women, and 1.29 (95% CI 1.02-1.63, 3 studies) for underweight women (supplementary Figure S2, available at Annals of Oncology online). Twelve additional studies reported results for obese versus non-obese women <12 months after diagnosis and the summary RR was 1.26 (95% CI 1.07-1.47, $I^2 = 80\%, P < 0.01$).

**dose-response meta-analysis.** There was evidence of a J-shaped association in the non-linear dose-response meta-analyses of BMI before and after diagnosis with total mortality (all $P < 0.01$) (Figure 3), suggesting that underweight women may be at slightly increased risk compared with normal weight women. The curves show linear increasing trends from 20 kg/m$^2$ for BMI before diagnosis and <12 months after diagnosis, and from 25 kg/m$^2$ for BMI ≥12 months after diagnosis. When linear models were fitted excluding the underweight category, the summary RRs of total mortality for each 5 kg/m$^2$ increase in BMI were 1.17 (95% CI 1.13-1.21, 15 studies, 6,358 deaths), 1.11 (95% CI 1.06-1.16, 12 studies, 6,020 deaths), and 1.08 (95% CI 1.01-1.15, 4 studies, 1,703 deaths) for BMI before, <12 months after, and ≥12 months after diagnosis, respectively (Figure 4). Substantial heterogeneity was observed between studies on BMI <12 months after diagnosis ($I^2 = 55\%, P = 0.01$).
**BMI and breast cancer mortality**

**categorical meta-analysis.** BMI was significantly associated with breast cancer mortality. Compared with normal weight women, for BMI before diagnosis, the summary RRs were 1.35 (95% CI 1.24-1.47, 22 studies) for obese women, 1.11 (95% CI 1.06-1.17, 21 studies) for overweight women, and 1.02 (95% CI 0.85-1.21, 8 studies) for underweight women (Figure 5). For BMI <12 months after diagnosis, the summary RRs were 1.25 (95% CI 1.10-1.42, 12 studies) for obese women, 1.11 (95% CI 1.03-1.20, 12 studies) for overweight women, and 1.53 (95% CI 1.27-1.83, 5 studies) for underweight women (supplementary Figure S3, available at Annals of Oncology online). Substantial heterogeneity was observed between studies of obese women ($I^2 = 53\%, P = 0.02$). For BMI ≥12 months after diagnosis, the summary RRs of the two studies identified were 1.68 (95% CI 0.90-3.15) for obese women and 1.37 (95% CI 0.96-1.95) for overweight women (supplementary Figure S4, available at Annals of Oncology online). The summary of another six studies that reported RRs for obese versus non-obese <12 months after diagnosis was 1.26 (95% CI 1.05-1.51, $I^2 = 64\%, P = 0.02$).

**dose-response meta-analysis.** There was no significant evidence of a non-linear relationship between BMI before, <12 months after, and ≥12 months after diagnosis and breast cancer mortality ($P = 0.21$, $P = 1.00$, $P = 0.86$ respectively) (Figure 3). When linear models were fitted excluding data from the underweight category, statistically significant increased risks of breast cancer mortality with BMI before and <12 months after diagnosis were observed (Figure 6). The summary RRs for each 5 kg/m^2 increase were 1.18 (95% CI 1.12-1.25, 18 studies, 5,262 breast cancer deaths) for BMI before diagnosis and 1.14 (95% CI 1.05-1.24, 8 studies, 3,857 breast cancer deaths) for BMI <12 months after diagnosis, with moderate ($I^2 = 47\%, P = 0.01$) and substantial ($I^2 = 66\%, P = 0.01$) heterogeneities between studies respectively. Only two studies on BMI ≥12 months after diagnosis and breast cancer...
mortality (N = 220 deaths) were identified. The summary RR was 1.29 (95% CI 0.97-1.72).

**BMI and other mortality outcomes**

Only two studies reported results for death from cardiovascular disease (N = 151 deaths)[27,112]. The summary RR for obese versus normal weight before diagnosis was 1.60 (95% CI 0.66-3.87). No association was observed for overweight versus normal weight (summary RR = 1.01, 95% CI 0.80-1.29). For each 5 kg/m$^2$ increase in BMI, the summary RR was 1.21 (95% CI 0.83-1.77). Five studies reported results for deaths from any cause other than breast cancer (N = 2,704 deaths)[21,34,108,113,114]. The summary RRs were 1.29 (95% CI 0.99-1.68, $I^2 = 72\%, P = 0.01$) for obese women, and 0.96 (95% CI 0.83-1.11, $I^2 = 26\%, P = 0.25$) for overweight women compared with normal weight women.

**Subgroup, meta-regression, and sensitivity analyses**

The results of the subgroup and meta-regression analyses are in supplementary Tables S3 and S4 (available at Annals of Oncology online). Subgroup analysis was not performed for BMI ≥12 months after diagnosis as the limited number of studies would hinder any meaningful comparisons.

Increased risks of mortality were observed in the meta-analyses by menopausal status. While the summary risk estimates seem stronger with premenopausal breast cancer, there was no significant heterogeneity between pre and postmenopausal breast cancer as shown in the meta-regression analyses ($P = 0.28-0.89$) (supplementary Table S3). For BMI before diagnosis and total mortality, the summary RRs for obese versus normal weight were 1.75 (95% CI 1.26-2.41, $I^2 = 70\%, P < 0.01$, 7 studies) in women with premenopausal breast cancer and 1.34 (95% CI 1.18-1.53, $I^2 = 27\%, P = 0.20$, 9 studies) in women with postmenopausal breast cancer.

Studies with larger number of deaths[105,115], conducted in Europe[28,115], or with weight and height assessed through medical records[28,104,115,116] tended to report weaker
associations for BMI <12 months after diagnosis and total mortality compared with other studies (meta-regression $P = 0.01, 0.02, 0.01$, respectively) (supplementary Table S3); while studies with larger number of deaths[101], conducted in Asia[101,102], or adjusted for comorbidity[101,102] reported weaker associations for BMI <12 months after diagnosis and breast cancer mortality (meta-regression $P = 0.01, 0.02, 0.01$, respectively) (supplementary Table S4).

Analyses stratified by study designs, or restricted to studies with invasive cases only, early-stage non-metastatic cases only, or mammography screening detected cases only, or controlled for previous diseases did not produce results that were materially different to those obtained in the overall analyses (results not shown). Summary risk estimates remained statistically significant when each study was omitted in turn, except for BMI $\geq 12$ months after diagnosis and total mortality. The summary RR was 1.06 (95% CI 0.98-1.15) per 5 kg/m$^2$ increase when Flatt et al.[117] which contributed 315 deaths was omitted.

**Small studies or publication bias**

Asymmetry was only detected in the funnel plots of BMI <12 months after diagnosis and total mortality, and breast cancer mortality, which suggests that small studies with an inverse association are missing (plots not shown). Egger’s tests were borderline significant ($P = 0.05$), or statistically significant ($P = 0.03$), respectively.

**discussion**

The present systematic literature review and meta-analysis of follow-up studies clearly supports that, in breast cancer survivors, higher BMI is consistently associated with lower overall and breast cancer survival, regardless of when BMI is ascertained. The limited number of studies on death from cardiovascular disease is also consistent with a positive association. For before, less than 12 months after, and 12 months or more after breast cancer
diagnosis, compared with normal weight women, obese women had 41%, 23%, and 21% higher risk for total mortality, and 35%, 25%, and 68% increased risk for breast cancer mortality, respectively. The findings were supported by the positive associations observed in the linear dose-response meta-analysis. All associations were statistically significant, apart from the relationship between BMI ≥12 months after diagnosis and breast cancer mortality. This may be due to limited statistical power, with only 220 breast cancer deaths from two follow-up studies.

Positive associations, in some cases statistically significant, were also observed in overweight, and underweight women compared with normal weight women. Women with BMI of 20 kg/m$^2$ before, or less than 12 months after diagnosis, and of 25 kg/m$^2$ 12 months or more after diagnosis appeared to have the lowest mortality risk in the non-linear dose-response analysis. Comorbid conditions may cause the observed increased risk in underweight women. Thorough investigation within the group and on their contribution to the shape of the association is hindered, as not all studies in this review reported results for this group. The increased risk associated with obesity was similar in pre or postmenopausal breast cancer. We did not find any evidence of a protective effect of obesity on survival after premenopausal breast cancer, contrary to what has been observed for the development of breast cancer in premenopausal women[4].

A large body of evidence with 41 477 deaths (23 182 from breast cancer) in over 210 000 breast cancer survivors was systematically reviewed in the present study. We carried out categorical, linear, and non-linear dose–response meta-analyses to examine the magnitude and the shape of the associations for total and cause-specific mortality in underweight, overweight, and obese women by time periods before and after diagnosis that is important in relation to the population-at-risk and breast cancer survivors. Our findings agree with and further extend the
results from previous meta-analyses. A review published in 2010 reported statistically
significant increased risks of 33% of both total and breast cancer mortality for obesity versus non-obesity around diagnosis[7]. These estimates are slightly higher than ours, which may be explained by the different search periods and inclusion criteria for the articles (33 studies and 15 studies included in the analyses, respectively). Another review published in 2012 further reported consistent positive associations of total and breast cancer mortality with higher versus lower BMI around diagnosis[6]. No significant differences were observed by menopausal status or hormone receptor status. The After Breast Cancer Pooling Project of four prospective cohort studies found differential effects of levels of pre-diagnosis obesity on survival[118]. Compared with normal weight women, significant or borderline significant increased risks of 81% of total and 40% of breast cancer mortality were only observed for morbidly obese (≥40 kg/m²) women and not for women in other obesity categories. We observed statistically significant increased risks also for overweight women, probably because of a larger number of studies. We were unable to investigate the associations with severely and morbidly obese women because only two studies included in this review reported such results[19,113]. Overall, our findings are consistent with previous meta-analyses in showing elevated total and breast cancer mortality associated with higher BMI.

A large body of evidence with 41,477 deaths (23,182 from breast cancer) in over 210,000 breast cancer survivors was systematically reviewed in the present study. We performed categorical, linear and non-linear dose-response meta-analyses to examine the magnitude and the shape of the associations for total and cause-specific mortality in underweight, overweight, and obese women by time periods before and after diagnosis; which to our knowledge, have not been done before using published data. Our findings support the current guidelines for breast cancer survivors to stay as lean as possible within the normal range of body weight[4], for overweight women to avoid weight gain during treatment and for obese
women to lose weight after treatment[119].

The present review is limited by the challenges and flaws encountered by the individual epidemiological studies evaluating the body fatness-mortality relationship in breast cancer survivors. Most studies did not adjust for comorbidities and assess intentional weight loss. Women with more serious health issues, and especially smokers, may lose weight but are at an increased risk of mortality and this might cause an apparent increased risk in underweight women. Body weight information through the natural history of the disease and treatment information were usually not complete or available. Increase of body weight post-diagnosis is common in women with breast cancer, particularly during chemotherapy[16]. Chemotherapy under-dosing is a common problem in obese women and may contribute to their increased mortality[120]. Although several studies with pre-diagnosis BMI adjusted for underlying illnesses or excluded the first few years of follow-up, reverse causation may have affected the results in studies that assessed BMI in women with cancer and other illnesses. However, in these studies the associations were similar to other studies. Possible survival benefit (subjects with better prognostic factors survive) may be present in the survival cohorts, in which the range of BMI could be narrower, and may cause an underestimation of the association. Follow-up studies with variable characteristics were pooled in the meta-analysis. Women identified in clinical trials may have had specific tumour subtypes, with fewer comorbidities, and were more likely to receive protocol treatments with high treatment completion rates. Women who were recruited through mammography screening programs may have had healthier lifestyles or access to medical facilities, and more likely to be diagnosed with in situ or early-stage breast cancer. Cancer detection methods, tumour classifications and treatment regimens change over time, and may vary within (if follow-up is long) and between studies, and could not be simply examined by using the diagnosis or treatment date. We cannot rule out the effect of unmeasured or residual confounding in our analysis. Nevertheless, most
results were adjusted for multiple confounding factors, including tumour stage or other-related variables and stratified analyses by several key factors showed similar summary risk estimates. Small study or publication bias was observed in the analyses of BMI <12 months after diagnosis. However, the overall evidence is supported by large, well-designed studies and is unlikely to be changed. We did not conduct analyses by race/ethnicity and treatment types as only limited studies had published results.

Future studies of body fatness and breast cancer outcomes should aim to account for comorbidities, separate intended and unintended changes of body weight, and collect complete treatment information during study follow-up. Randomised clinical trials are needed to test interventions for weight loss and maintenance on survival in women with breast cancer.

In conclusion, the present systematic literature review and meta-analysis extend and confirms the associations of overweight and obesity with an unfavourable overall and breast cancer survival in pre and postmenopausal breast cancer, regardless of when BMI is ascertained. Given the comparable elevated risks with obesity in the development (for postmenopausal women) and prognosis of breast cancer, and the complications with cancer treatment and other obesity-related comorbidities, it is prudent to maintain a healthy body weight (BMI 18.5 to <25.0 kg/m$^2$) throughout life.

**acknowledgements**

TN is the principal investigator of the Continuous Update Project at Imperial College London. TN and DSMC wrote the protocol and implemented the study with the advice of an expert committee convened by WCRF. RV developed and managed the database for the Continuous Update Project. DSMC, TN, and DA did the literature search and study selections. DSMC, ARV, DNR did the data extraction. DSMC carried out the statistical analyses. DCG was statistical adviser and contributed to the statistical analyses. DSMC wrote
the first draft of the original manuscript. EB, AM, and IT are panel members of the Continuous Update Project and advised on the interpretation of the review. All authors revised the manuscript. DSMC takes responsibility for the integrity of the data and the accuracy of the data analysis.

**funding**
This work was supported by the World Cancer Research Fund International (grant number: 2007/SP01) (http://www.wcrf-uk.org/). The funder of this study had no role in the decisions about the design and conduct of the study; collection, management, analysis, or interpretation of the data; or the preparation, review, or approval of the manuscript. The views expressed in this review are the opinions of the authors. They may not represent the views of the World Cancer Research Fund International/American Institute for Cancer Research and may differ from those in future updates of the evidence related to food, nutrition, physical activity, and cancer survival.

**disclosure**
DCG reports personal fees from World Cancer Research Fund/American Institute for Cancer Research, during the conduct of the study; grants from Danone, and grants from Kelloggs, outside the submitted work. AM reports personal fees from Metagenics/Metaproteomics, personal fees from Pfizer, outside the submitted work. All remaining authors have declared no conflicts of interest.

**references**


54. Anderson SJ, Wapnir I, Dignam JJ et al. Prognosis after ipsilateral breast tumor


80. Saxe GA, Rock CL, Wicha MS et al. Diet and risk for breast cancer recurrence and


women who are less overweight and eat less fat. The Iowa Women's Health Study. Cancer 1995; 76: 275-283.


Table 1. Summary of meta-analyses of BMI and survival in women with breast cancer

BMI before and after diagnosis (<12 months after, or ≥12 months after diagnosis) was classified according to the exposure period which the studies referred to in the BMI assessment; the BMI categories were included in the categorical meta-analyses as defined by the studies

\( P_h – P \) for heterogeneity between studies

Figure 1. Flowchart of search

Figure 2. Categorical meta-analysis of pre-diagnosis BMI and total mortality

Figure 3. Non-linear dose-response curves of BMI and mortality

Figure 4. Linear dose-response meta-analysis of BMI and total mortality

Figure 5. Categorical meta-analysis of pre-diagnosis BMI and breast cancer mortality

Figure 6. Linear dose-response meta-analysis of BMI and breast cancer mortality

Supplementary Table S1. Characteristics of studies included in the meta-analyses of BMI and survival in women with breast cancer

Abbreviations: BC=breast cancer; BMI=body mass index; ht=height; max=maximum; min=minimum; MV=multivariate; QI=Quetelet index; wt=weight

Supplementary Table S2. Characteristics of studies excluded in the meta-analyses of BMI and survival in women with breast cancer

Abbreviations: BC=breast cancer; BMI=body mass index; ht=height; max=maximum; min=minimum; MV=multivariate; QI=Quetelet index; wt=weight

Supplementary Table S3. Subgroup meta-analyses of BMI and total mortality in women with breast cancer

\( P_h^a – \) within subgroups; \( P_h^b – \) between subgroups with meta-regression analysis

Supplementary Table S4. Subgroup meta-analyses of BMI and breast cancer mortality in women with breast cancer

\( P_h^a – \) within subgroups; \( P_h^b – \) between subgroups with meta-regression analysis

Supplementary Figure S1. Categorical meta-analysis of BMI <12 months after diagnosis and total mortality

Supplementary Figure S2. Categorical meta-analysis of BMI ≥12 months after diagnosis and total mortality
Supplementary Figure S3. Categorical meta-analysis of BMI <12 months after diagnosis and breast cancer mortality

Supplementary Figure S4. Categorical meta-analysis of BMI ≥12 months after diagnosis and breast cancer mortality
Table 1. Summary of meta-analyses of BMI and survival in women with breast cancer

BMI before and after diagnosis (<12 months after, or ≥12 months after diagnosis) was classified according to the exposure period which the studies referred to in the BMI assessment; the BMI categories were included in the categorical meta-analyses as defined by the studies

P<sub>h</sub> – P for heterogeneity between studies

<table>
<thead>
<tr>
<th></th>
<th>BMI before diagnosis</th>
<th>BMI &lt;12 months after diagnosis</th>
<th>BMI ≥12 months after diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>RR (95% CI)</td>
<td>I&lt;sup&gt;2&lt;/sup&gt; (%)</td>
</tr>
<tr>
<td><strong>Total mortality</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underweight v normal weight</td>
<td>10</td>
<td>1.10 (0.92 to 1.31)</td>
<td>48</td>
</tr>
<tr>
<td>Overweight v normal weight</td>
<td>19</td>
<td>1.07 (1.02 to 1.12)</td>
<td>0</td>
</tr>
<tr>
<td>Obese v normal weight</td>
<td>21</td>
<td>1.41 (1.29 to 1.53)</td>
<td>38</td>
</tr>
<tr>
<td>Obese v non to obese</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per 5 kg/m&lt;sup&gt;2&lt;/sup&gt; increase</td>
<td>15</td>
<td>1.17 (1.13 to 1.21)</td>
<td>7</td>
</tr>
<tr>
<td><strong>Breast cancer mortality</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underweight v normal weight</td>
<td>8</td>
<td>1.02 (0.85 to 1.21)</td>
<td>31</td>
</tr>
<tr>
<td>Overweight v normal weight</td>
<td>21</td>
<td>1.11 (1.06 to 1.17)</td>
<td>0</td>
</tr>
<tr>
<td>Obese v normal weight</td>
<td>22</td>
<td>1.35 (1.24 to 1.47)</td>
<td>36</td>
</tr>
<tr>
<td>Obese v non-obese</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per 5 kg/m&lt;sup&gt;2&lt;/sup&gt; increase</td>
<td>18</td>
<td>1.18 (1.12 to 1.25)</td>
<td>47</td>
</tr>
<tr>
<td><strong>Cardiovascular disease related mortality</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overweight v normal weight</td>
<td>2</td>
<td>1.01 (0.80 to 1.29)</td>
<td>0</td>
</tr>
<tr>
<td>Obese v normal weight</td>
<td>2</td>
<td>1.60 (0.66 to 3.87)</td>
<td>78</td>
</tr>
<tr>
<td>Per 5 kg/m&lt;sup&gt;2&lt;/sup&gt; increase</td>
<td>2</td>
<td>1.21 (0.83 to 1.77)</td>
<td>80</td>
</tr>
<tr>
<td><strong>Non-breast cancer mortality</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overweight v normal weight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obese v normal weight</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Figure 1. Flowchart of search

22590 unique records identified in Pubmed and Embase until 30 June 2013 and 19 articles found in handsearch → 21566 records excluded on the basis of title and abstract

1043 full-text articles retrieved and assessed for inclusion → 651 articles excluded for not fulfilling the inclusion criteria
87 no original data
338 did not report on the associations of interest
33 abstract/commentary
10 meta-analyses
183 irrelevant study design

392 articles potentially relevant articles in women with breast cancer → 268 articles did investigate body fatness and mortality

124 articles on body fatness and mortality

79 relevant articles (82 studies) on body mass index and mortality included in the meta-analyses in present review → 31 articles excluded in present review

4 examined obesity index
12 no measure of association
15 superseded publications
14 articles excluded in meta-analysis
5 insufficient data
8 unadjusted results
Figure 2. Categorical meta-analysis of pre-diagnosis BMI and total mortality

<table>
<thead>
<tr>
<th>Study</th>
<th>RR (95% CI)</th>
<th>% Weight</th>
<th>BMI kg/m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underweight v normal weight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buck 2011</td>
<td>1.98 (0.79, 4.96)</td>
<td>3.29</td>
<td>&lt;18.5 v 18.5-24.9</td>
</tr>
<tr>
<td>Conroy 2011</td>
<td>1.13 (0.89, 1.42)</td>
<td>17.23</td>
<td>&lt;22.5 v 22.5-24.9</td>
</tr>
<tr>
<td>Lu 2011</td>
<td>0.89 (0.70, 1.14)</td>
<td>18.79</td>
<td>&lt;20 v 20-24.9</td>
</tr>
<tr>
<td>Chen 2010</td>
<td>1.44 (0.88, 2.37)</td>
<td>8.51</td>
<td>&lt;18.4 v 18.5-24.9</td>
</tr>
<tr>
<td>Ennals 2010</td>
<td>1.70 (0.86, 3.33)</td>
<td>5.44</td>
<td>&lt;18.4 v 18.5-24.9</td>
</tr>
<tr>
<td>Hellmann 2010</td>
<td>1.36 (0.87, 2.11)</td>
<td>9.79</td>
<td>&lt;19.9 v 19-20.5</td>
</tr>
<tr>
<td>Nichols 2009</td>
<td>1.75 (0.94, 3.25)</td>
<td>6.21</td>
<td>&lt;18.4 v 18.5-24.9</td>
</tr>
<tr>
<td>Abrahamson 2006</td>
<td>0.73 (0.52, 1.04)</td>
<td>12.75</td>
<td>&lt;18.4 v 18.5-24.9</td>
</tr>
<tr>
<td>Kronke 2005</td>
<td>0.89 (0.70, 1.13)</td>
<td>16.98</td>
<td>&lt;21 v 21-22</td>
</tr>
<tr>
<td>Bernstein 2002</td>
<td>1.13 (0.43, 2.97)</td>
<td>3.01</td>
<td>&lt;18.4 v 18.5-24.9</td>
</tr>
<tr>
<td>Subtotal (I² squared = 48.2%, P = 0.045)</td>
<td>1.10 (0.02, 3.11)</td>
<td>100.00</td>
<td></td>
</tr>
<tr>
<td>Overweight v normal weight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamineni 2013</td>
<td>1.09 (0.69, 1.79)</td>
<td>1.18</td>
<td>25-29.9 v &lt;25</td>
</tr>
<tr>
<td>Buck 2011</td>
<td>1.03 (0.69, 1.56)</td>
<td>1.47</td>
<td>25-29.9 v 18.5-24.9</td>
</tr>
<tr>
<td>Conroy 2011</td>
<td>1.15 (0.93, 1.42)</td>
<td>5.47</td>
<td>25-29.9 v 22.5-24.9</td>
</tr>
<tr>
<td>Lu 2011</td>
<td>0.99 (0.84, 1.15)</td>
<td>9.94</td>
<td>25-29.9 v 20-24.9</td>
</tr>
<tr>
<td>Chen 2010</td>
<td>1.02 (0.81, 1.27)</td>
<td>4.85</td>
<td>25-29.9 v 18.5-24.9</td>
</tr>
<tr>
<td>Ennals 2010</td>
<td>1.02 (0.81, 1.27)</td>
<td>4.85</td>
<td>25-29.9 v 18.5-24.9</td>
</tr>
<tr>
<td>Hellmann 2010</td>
<td>1.22 (0.92, 1.61)</td>
<td>3.13</td>
<td>25-30 v 20-25</td>
</tr>
<tr>
<td>Kearon 2010</td>
<td>1.16 (0.92, 1.45)</td>
<td>4.74</td>
<td>25-29.9 v &lt;24.9</td>
</tr>
<tr>
<td>Nichols 2009</td>
<td>1.13 (0.90, 1.42)</td>
<td>4.71</td>
<td>25-29.9 v 18.5-24.9</td>
</tr>
<tr>
<td>West-Wright 2009</td>
<td>0.98 (0.78, 1.24)</td>
<td>4.56</td>
<td>25-29.9 v &lt;24</td>
</tr>
<tr>
<td>Caan 2006</td>
<td>1.20 (0.80, 1.70)</td>
<td>1.73</td>
<td>25-29.9 v &lt;24.9</td>
</tr>
<tr>
<td>Dai Miao 2008</td>
<td>1.02 (0.83, 1.25)</td>
<td>5.85</td>
<td>25-29.9 v &lt;24.9</td>
</tr>
<tr>
<td>Peeling 2008</td>
<td>1.20 (0.90, 1.60)</td>
<td>2.98</td>
<td>25-29.9 v &lt;24.9</td>
</tr>
<tr>
<td>Reeves 2007</td>
<td>1.02 (0.94, 1.12)</td>
<td>32.69</td>
<td>25-30 v 18.5-25</td>
</tr>
<tr>
<td>Abrahamson 2006</td>
<td>1.47 (0.98, 2.24)</td>
<td>1.37</td>
<td>25-29.9 v 18.5-24.9</td>
</tr>
<tr>
<td>Kronke 2005</td>
<td>1.11 (0.91, 1.34)</td>
<td>6.55</td>
<td>25-29 v 21-22</td>
</tr>
<tr>
<td>Reeves 2000</td>
<td>1.19 (0.92, 1.53)</td>
<td>3.79</td>
<td>25-26 v &lt;24</td>
</tr>
<tr>
<td>Zhang 1995</td>
<td>1.00 (0.83, 1.23)</td>
<td>0.23</td>
<td>24.7-28.8 v 16-24.6</td>
</tr>
<tr>
<td>Holmberg 1994</td>
<td>2.38 (0.84, 6.77)</td>
<td>0.23</td>
<td>25-28 v &lt;19</td>
</tr>
<tr>
<td>Subtotal (I² squared = 0.0%, P = 0.882)</td>
<td>1.07 (1.02, 1.12)</td>
<td>100.00</td>
<td></td>
</tr>
<tr>
<td>Obese v normal weight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamineni 2010</td>
<td>1.31 (0.77, 2.22)</td>
<td>2.20</td>
<td>&gt;30 v &lt;25</td>
</tr>
<tr>
<td>Buck 2011</td>
<td>1.15 (0.54, 2.45)</td>
<td>1.17</td>
<td>&gt;30 v 18.5-24.9</td>
</tr>
<tr>
<td>Conroy 2011</td>
<td>1.54 (1.23, 1.91)</td>
<td>7.31</td>
<td>&gt;30 v 22.5-24.9</td>
</tr>
<tr>
<td>Lu 2011</td>
<td>1.23 (1.04, 1.47)</td>
<td>6.97</td>
<td>&gt;30 v 20-24.9</td>
</tr>
<tr>
<td>Chen 2010</td>
<td>1.58 (1.13, 2.22)</td>
<td>4.42</td>
<td>&gt;30 v 18.5-24.9</td>
</tr>
<tr>
<td>Ennals 2010</td>
<td>1.47 (1.08, 1.99)</td>
<td>5.05</td>
<td>&gt;30 v 18.5-24.9</td>
</tr>
<tr>
<td>Hellmann 2010</td>
<td>1.61 (1.12, 2.33)</td>
<td>3.94</td>
<td>&gt;30 v 20-25</td>
</tr>
<tr>
<td>Kearon 2010</td>
<td>1.21 (1.06, 1.48)</td>
<td>8.12</td>
<td>&gt;30 v &lt;24.9</td>
</tr>
<tr>
<td>Nichols 2006</td>
<td>1.52 (1.17, 1.98)</td>
<td>6.05</td>
<td>&gt;30 v 18.5-24.9</td>
</tr>
<tr>
<td>West-Wright 2009</td>
<td>1.42 (1.08, 1.88)</td>
<td>5.70</td>
<td>&gt;30 v &lt;25</td>
</tr>
<tr>
<td>Caan 2006</td>
<td>1.60 (1.10, 2.30)</td>
<td>3.00</td>
<td>&gt;30 v &lt;24.9</td>
</tr>
<tr>
<td>Dai Miao 2008</td>
<td>1.29 (0.98, 1.68)</td>
<td>8.02</td>
<td>&gt;30 v &lt;24.9</td>
</tr>
<tr>
<td>Peeling 2008</td>
<td>1.39 (1.46, 2.00)</td>
<td>5.39</td>
<td>&gt;25.8 v &lt;20.5</td>
</tr>
<tr>
<td>Cleveland 2007</td>
<td>1.63 (1.08, 2.45)</td>
<td>3.34</td>
<td>&gt;30 v &lt;24.9</td>
</tr>
<tr>
<td>Reeves 2007</td>
<td>1.06 (0.86, 1.30)</td>
<td>7.67</td>
<td>&gt;30 v 18.5-24.9</td>
</tr>
<tr>
<td>Abrahamson 2006</td>
<td>2.93 (1.37, 5.29)</td>
<td>1.16</td>
<td>&gt;30 v 18.5-24.9</td>
</tr>
<tr>
<td>Kronke 2005</td>
<td>1.00 (0.95, 1.05)</td>
<td>6.85</td>
<td>&gt;30 v 20-22</td>
</tr>
<tr>
<td>Bernstein 2002</td>
<td>1.18 (0.81, 1.72)</td>
<td>3.78</td>
<td>&gt;25 v 18.5-24.9</td>
</tr>
<tr>
<td>Reeves 2000</td>
<td>1.49 (1.18, 1.86)</td>
<td>7.08</td>
<td>&gt;27 v &lt;24</td>
</tr>
<tr>
<td>Zhang 1995</td>
<td>1.50 (0.70, 2.93)</td>
<td>1.31</td>
<td>28.9-45.9 v 16-24.6</td>
</tr>
<tr>
<td>Holmberg 1994</td>
<td>5.93 (1.98, 17.80)</td>
<td>0.58</td>
<td>&gt;29 v &lt;19</td>
</tr>
<tr>
<td>Subtotal (I² squared = 37.6%, P = 0.045)</td>
<td>1.41 (1.29, 1.53)</td>
<td>100.00</td>
<td></td>
</tr>
</tbody>
</table>
Figure 3. Non-linear dose-response curves of BMI and mortality
Figure 4. Linear dose-response meta-analysis of BMI and total mortality
Figure 5. Categorical meta-analysis of pre-diagnosis BMI and breast cancer mortality
Figure 6. Linear dose-response meta-analysis of BMI and breast cancer mortality